Lv4
480 积分 2022-03-30 加入
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
24天前
已完结
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy
2个月前
已完结
How I treat post-immunotherapy relapsed B-ALL
3个月前
已完结
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
4个月前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
5个月前
已关闭
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
5个月前
已完结
CAR T Cells — A New Horizon for Autoimmunity?
8个月前
已完结
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
8个月前
已完结
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
8个月前
已完结
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
9个月前
已完结
皖公网安备34019202002308
